Please assess the completion status of the following clinical trial:

Trial Title: Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Ability to provide written informed consent and HIPAA authorization~2. Male and female subjects ≥ 18 years of age at the time of informed consent~3. Histologically confirmed diagnosis of mycosis fungoides (MF) T-cell lymphoma~4. Advanced disease as defined by Stage IB (is when ten percent or more of the skin surface is covered with patches, papules, and/or plaques), II-A, II-B, III and IV; disease unresponsive to or contraindicated for skin directed therapy (light treatment, electron beam radiation, topical nitrogen mustards, topical steroids); or otherwise a candidate for systemic therapy due to disease progression~5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1~6. Post resolution of all clinically significant toxic effects of prior cancer therapy to Grade ≤ 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03 (NCI-CTCAE, v.4.03)~7. Adequate hematologic and metabolic functions to tolerate gemcitabine.~Exclusion Criteria:~1. Lack of enough skin disease burden to adequately obtain 3 6-mm skin biopsies for ex vivo BDI assessment.~2. Clinical evidence of central nervous system (CNS) metastasis.~3. Psychiatric illness, disability or social situation that would compromise the subject's safety or ability to provide consent, or limit compliance with study requirements~4. Inability or refusal to receive systemic therapy with gemcitabine~5. Prior treatment with gemcitabine~6. Pre-existing allergy to or otherwise contraindicated to receive gemcitabine~7. Patients not on a stable dose of systemic corticosteroid for at least 4 weeks prior to study entry or ≥ 20 mg prednisone daily equivalent~8. Subjects actively on other systemic therapeutic agents for cancer including MF, or would reasonably be expected to receive such treatments during the study period, including ≥ 20 mg prednisone equivalent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Individuals undergoing SOC Gemcitabine Treatment for mycosis fungoides (MF) T-cell lymphoma (Type: OTHER): Standard of Care (SOC) treatment with gemcitabine in this setting is 1200 mg/m2 as a 30 minute infusion given intravenously on days 1, 8, and 15 of every 28-day treatment cycle. Standard dose reductions are expected in patients experiencing unacceptable toxic effects of treatment. All subjects will undergo standardized staging tests, with tumor stage defined according to established guidelines. For this study, three 6-mm x 4-mm dermal punch biopsies from one or more target lesions will be collected prior to treatment initiation and submitted for Biodynamic imaging (BDI). All patients will be considered off-study after completing cycle 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).